• 1
    Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26: 681686.
  • 2
    Trulock EP, Christie JD, Edwards LB, et al. Registry of the international society for heart and lung transplantation: Twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26: 782795.
  • 3
    Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 12291242.
  • 4
    Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung rejection study group. J Heart Lung Transplant 1996; 15(1 Pt 1): 115.
  • 5
    Belperio JA, Weigt SS, Fishbein MC, Lynch JP, 3rd. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108121.
  • 6
    Weigt SS, Wallace WD, Derhovanessian A, Saggar R, Lynch JP, Belperio JA. Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 2010; 31: 189207.
  • 7
    Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 10731086.
  • 8
    Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182: 784789.
  • 9
    Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 13911396.
  • 10
    Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the Allograft after lung transplantation and the risk of Bronchiolitis Obliterans Syndrome. Transplantation 2008; 85: 771774.
  • 11
    Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170: 181187.
  • 12
    Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 2008; 31: 10371045.
  • 13
    Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 20312036.
  • 14
    Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 19031911.
  • 15
    Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: An update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 2010; 150: 406417.
  • 16
    Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004; 1: 315320.
  • 17
    Heyder J GJ, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci 1986; 17: 811825.
  • 18
    Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005; 172: 14971504.
  • 19
    Gerrity TR, Lee PS, Hass FJ, Marinelli A, Werner P, Lourenco RV. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol 1979; 47: 867873.
  • 20
    Weigt SS, Finlen Copeland CA, Derhovanessian A, et al. A multi-center validation of pulmonary aspergillus fumigatus colonization as a risk factor for bronchiolitis obliterans syndrome after lung transplantation [abstract]. Am J Respir Crit Care Med 2011; 183(A4020).
  • 21
    Hartwig MG, Snyder LD, Finlen-Copeland A, et al. Lung transplantation at Duke University. Clin Transpl 2009: 197210.
  • 22
    De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 18131821.
  • 23
    Vanev S. Aspergillus and Penicillium. In.: CBS Fungal Biodiversity Centre, 2011.
  • 24
    Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297310.
  • 25
    Burton CM, Iversen M, Mortensen J, et al. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: An important confounder? J Heart Lung Transplant 2007; 26: 11271134.
  • 26
    Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2009; 47(Suppl 1): S261S270.